Drug · CHEMBL895
NALBUPHINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. NALBUPHINE. Drugs and targets, record CHEMBL895. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL895
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| OPRD1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4985 |
| OPRK1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4986 |
| OPRM1 | Opioid receptors; mu/kappa/delta | Opioid receptors; mu/kappa/delta agonist | AGONIST | https://conductscience.org/library/genes/4988 |
Source ChEMBL
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials96
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03497975 | PRISM Study-Pruritus Relief Through Itch Scratch Modulation | Phase 2/3 | 353 | 2025-06-24 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT02820051 | Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy | 102 | 2024-12-02 | nalbuphine | Its name | ClinicalTrials.gov | |
| NCT02174419 | Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis | Phase 2/3 | 62 | 2020-08-21 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT04018664 | Oral Abuse Potential Study of Nalbuphine | Phase 1 | 56 | 2020-08-31 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT00716807 | Efficacy of Nalbuphine and Naloxone Administered as Nose Sprays in the Treatment of Orofacial Pain | 46 | 2013-10-22 | nalbuphine | Its name | ClinicalTrials.gov | |
| NCT04030026 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | Phase 2 | 42 | 2025-05-29 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT01380197 | Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally | Phase 3 | 40 | 2015-02-16 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT02174432 | Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis | Phase 2/3 | 36 | 2020-10-23 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT04020016 | Study of Nalbuphine ER in Participants With Hepatic Impairment | Phase 1 | 28 | 2026-03-19 | nalbuphine | Its name | ClinicalTrials.gov |
| NCT00947284 | Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity | 3 | 2013-10-23 | nalbuphine | Its name | ClinicalTrials.gov |
1 to 10 of 96
See all 96 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Midazolam vs Propofol: deaths from any cause | 0 of 49 | 0 of 53 | 102 | NCT02820051 | Trial comparisons |
| Midazolam vs Propofol: serious adverse events | 0 of 49 | 0 of 53 | 102 | NCT02820051 | Trial comparisons |
| NAL ER vs Placebo: deaths from any cause | 0 of 42 | 0 of 42 | 84 | NCT04030026 | Trial comparisons |
| NAL ER vs Placebo: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiogram (ECG) | 1 of 38 | 1 of 40 | 78 | NCT04030026 | Trial comparisons |
| NAL ER vs Placebo: Number of Participants With Clinically Significant Changes in Physical Examination Parameters | 0 of 38 | 0 of 40 | 78 | NCT04030026 | Trial comparisons |
| NAL ER vs Placebo: Number of Participants With Clinically Significant Changes in Vital Sign Parameters | 0 of 38 | 0 of 40 | 78 | NCT04030026 | Trial comparisons |
| NAL ER vs Placebo: Number of Participants Who Experienced at Least One Treatment Emergent Adverse Events (TEAEs) | 35 of 38 | 26 of 40 | 78 | NCT04030026 | Trial comparisons |
| NAL ER vs Placebo: serious adverse events | 1 of 38 | 1 of 40 | 78 | NCT04030026 | Trial comparisons |
| Randomizing Particiipants to Morphine vs Randomization to Nubain: Number of Participants Who Experienced Pain Relief | 2 of 20 | 2 of 20 | 40 | NCT01380197 | Trial comparisons |
| Randomizing Particiipants to Morphine vs Randomization to Nubain: Acute Chest Syndrome | 2 of 20 | 1 of 20 | 40 | NCT01380197 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials31
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Contour Integration Task | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL895
GET https://conductscience.org/api/drugs/v1/CHEMBL895/trials?page=2